Long-term production of erythropoietin after electroporation-mediated transfer of plasmid DNA into the muscles of normal and uremic rats

Gene Therapy
H MaruyamaJ Miyazaki

Abstract

The anemia associated with chronic renal failure is one of the best target diseases for erythropoietin (Epo) gene transfer. We previously reported a short-term (1 month) study of continuous rat Epo delivery by muscle-targeted gene transfer of plasmid DNA expressing rat Epo (pCAGGS-Epo) using in vivo electroporation in normal rats. Here, we performed a long-term pharmacokinetic study of continuous Epo delivery by this method in normal rats and uremic five-sixths nephrectomized rats. In normal rats, Epo gene expression and sufficient erythropoiesis occurred with Epo gene transfer in a dose-dependent manner, and persisted for at least 11 weeks. Repeated administration of the plasmid DNA effectively produced erythropoiesis. Similar erythropoiesis was observed in the uremic rats, and persisted for more than 15 weeks. Both normal and uremic rats showed a significant decrease in platelet count. Moreover, the uremic rats showed Epo-induced hypertension, which is the major side-effect of recombinant human Epo. These results demonstrate that muscle-targeted pCAGGS-Epo transfer by in vivo electroporation is a useful procedure for the long-term continuous delivery of Epo in both normal and uremic rats.

References

Sep 1, 1992·Human Molecular Genetics·J A WolffA Jani
Mar 23, 1990·Science·J A WolffP L Felgner
Jul 1, 1986·Molecular and Cellular Biology·N BeruE Goldwasser
Jul 1, 1986·Jikken dobutsu. Experimental animals·K Ohwada
Jul 1, 1986·Molecular and Cellular Biology·M C Bondurant, M J Koury
Aug 15, 1995·Proceedings of the National Academy of Sciences of the United States of America·W R OsborneA W Clowes
Apr 1, 1995·The Journal of Clinical Investigation·Y HamamoriL Kedes
Nov 1, 1994·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·D RothC A Shadur
Oct 1, 1995·Clinical and Experimental Pharmacology & Physiology·J M PouxC Leroux-Robert
Oct 1, 1996·Proceedings of the National Academy of Sciences of the United States of America·S K TripathyJ M Leiden
Jan 20, 1997·Human Gene Therapy·D Bohl, J M Heard
May 1, 1997·Clinical and Experimental Hypertension : CHE·S Lacasse-MM Lebel
Sep 22, 1998·Nature Biotechnology·H Aihara, J Miyazaki
May 26, 1999·Proceedings of the National Academy of Sciences of the United States of America·G RizzutoE Fattori

❮ Previous
Next ❯

Citations

Jul 12, 2002·The Journal of Gene Medicine·H MaruyamaF Gejyo
Dec 3, 2002·Current Opinion in Biotechnology·Pascal BigeyDaniel Scherman
Nov 23, 2012·Animal : an International Journal of Animal Bioscience·T F CollaresT Collares
Feb 28, 2002·Human Gene Therapy·Hiroki MaruyamaJun-Ichi Miyazaki
Feb 8, 2003·DNA and Cell Biology·Ann E O Trezise
Mar 23, 2007·Human Gene Therapy·Magdolna G SebestyénJon A Wolff
Jun 30, 2007·BMC Molecular Biology·Pernille HojmanJulie Gehl
Mar 13, 2008·Genetic Vaccines and Therapy·Emmanuelle E FabreEmmanuel Payen
May 27, 2004·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Jillian M McMahon, Dominic J Wells
Mar 10, 2004·Internal Medicine·Enyu Imai, Yoshitaka Isaka
Sep 21, 2007·Expert Opinion on Drug Delivery·Yoshitaka Isaka, Enyu Imai
Apr 7, 2007·Journal of Neuropathology and Experimental Neurology·Suzanne M de la MonteJack R Wands
Sep 20, 2005·Biotechnology and Bioengineering·Yasuhiro OgawaShintaro Nishimura
Dec 8, 2009·Medicinal Research Reviews·Ainhoa MuruaJosé Luis Pedraz
Nov 19, 2002·Biochemical and Biophysical Research Communications·Virginie DeleuzeMichel F Bureau
Sep 19, 2003·Biochemical and Biophysical Research Communications·S KamedaF Gejyo
Nov 14, 2007·Methods in Enzymology·Wolfgang Jelkmann
Mar 11, 2003·Technology in Cancer Research & Treatment·Daniel SchermanMichel Francis Bureau
Dec 23, 2006·Clinical and Experimental Nephrology·Yoshitaka Isaka
Jun 16, 2004·Laboratory Investigation; a Journal of Technical Methods and Pathology·Yukio UmedaHirofumi Takemura
May 5, 2006·Journal of the American Society of Nephrology : JASN·Nicoletta EliopoulosJacques Galipeau
Jan 23, 2002·Gene Therapy·H MaruyamaJ Miyazaki
Feb 7, 2003·Gene Therapy·Q L LuT A Partridge
Oct 31, 2002·Uchū Seibutsu Kagaku·Shinji Komazaki
Mar 7, 2006·The Journal of Gene Medicine·Tatsufumi MurakamiAkihiro Nakamura
Jun 9, 2019·International Journal of Molecular Sciences·Emilia Sokołowska, Agnieszka Urszula Błachnio-Zabielska
Jul 4, 2003·American Journal of Physiology. Cell Physiology·Anne BertrandDavid Tuil
Oct 30, 2004·The Journal of Gene Medicine·Elena FattoriNicola La Monica
Jun 25, 2002·Biology of Reproduction·Thomas R MageeNestor F Gonzalez-Cadavid
Nov 3, 2004·The Journal of Gene Medicine·Yun Chau LongOi Lian Kon
Mar 28, 2003·Journal of the American Society of Nephrology : JASN·Enyu Imai
May 23, 2003·Journal of the American Society of Nephrology : JASN·Hideaki ShimizuSeiichi Matsuo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.